Trials / Unknown
UnknownNCT04457869
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
A Phase 2, Open-label, Single-arm, Multicenter Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of F520 for the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F520 | 3mg/kg every 3 weeks |
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2022-07-31
- Completion
- 2023-01-01
- First posted
- 2020-07-07
- Last updated
- 2020-10-22
Source: ClinicalTrials.gov record NCT04457869. Inclusion in this directory is not an endorsement.